m6A-Coupled Effector Protein Expression System for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for addressing m6A dysregulation in cancer, such as inhibiting m(6)A methyltransferase, can have unintended effects on non-pathological tissues, highlighting the need for targeted approaches to decrease m6A hypermethylation and expression of upregulated oncogenes.
Innovation Solution
A N6-methyladenosine (m6A)-coupled effector protein expression system is developed, comprising a fusion protein with an m6A binding domain and a catalytic domain of cytidine deaminase, along with a nucleic acid sequence encoding an effector protein and dihydrofolate reductase, to specifically target and modulate m6A-dependent protein expression in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If m(6)A methyltransferase is inhibited to decrease m6A hypermethylation, then expression of upregulated oncogenes is reduced, but unwanted effects occur on non-pathological tissues
Solution Approach 1:
The patent applies local quality by designing an m6A sensor sequence with specific sequence context (GAC motifs) that is incorporated only into the effector protein mRNA in cancer cells. This creates a localized m6A modification pattern that distinguishes target cells from non-pathological tissues, enabling selective protein expression only where the sensor sequence is present and methylated.
Solution Approach 2:
The patent uses an m6A sensor sequence as an intermediary element that couples m6A methylation status to effector protein expression. The sensor sequence acts as a mediator between the m6A methyltransferase machinery and the effector protein, translating methylation status into selective protein expression. This intermediary mechanism ensures that only cells with the specific sensor sequence and appropriate m6A methylation will express the effector protein.
2Reliability
If targeted approaches are used to decrease m6A hypermethylation in cancer cells, then oncogene expression is reduced, but device complexity increases
Solution Approach 1:
The patent merges multiple functions into a single integrated system: the effector protein coding sequence, the m6A sensor sequence, and the dihydrofolate reductase domain are combined into one mRNA transcript. This merging simplifies the overall system by eliminating the need for separate regulatory components and achieving targeted expression through a single transcriptional unit that responds to m6A methylation status.
Solution Approach 2:
The patent creates a universal m6A-coupled expression system that can target multiple different oncogenes and cancer types by simply changing the effector protein coding sequence while maintaining the same m6A sensor sequence architecture. The system is multi-functional, capable of delivering various effector proteins (e.g., tumor suppressors, RNA-guided endonucleases) through a standardized m6A-responsive platform.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system allows for precise regulation of m6A-dependent protein expression, reducing m6A hypermethylation and inhibiting cancer cell proliferation, migration, and metastasis, while minimizing effects on non-pathological cells.
Implementation Method 1
an m6A binding domain of a YT521-B homology (YTH) domain-containing protein
Implementation Method 2
a catalytic domain of a cytidine deaminase
Data Source
AI summary
The present disclosure provides systems and methods for m6A-dependent delivery and m6A-dependent delivery targeted of a polypeptide to a cell. In certain embodiments, compositions, systems, and methods are provided that provide for m6A-dependent delivery of effector proteins, for example, effector proteins, such as a tumor suppression proteins and m6a regulation systems, mediated by CRISPRi in embodiments.